Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 1/20 | 0.61 |
| ▸ | HTR2A | P28223 | 2/20 | 0.45 |
| ▸ | HTR2C | P28335 | 2/20 | 0.45 |
| ▸ | HTR2B | P41595 | 2/20 | 0.45 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.43 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | PARP1 | P09874 | 2/20 | 0.41 |
| ▸ | MGLL | Q99685 | 7/20 | 0.41 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.41 |
| ▸ | CTSG | P08311 | 1/20 | 0.40 |
| ▸ | CMA1 | P23946 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4714835 | 0.91 | BDKRB1 (0.60) | BDKRB1HTR2AHTR2CHTR2BGRM1 | |
| SCHEMBL5628754 | 0.91 | BDKRB1 (0.57) | BDKRB1HTR2AHTR2CHTR2BGRM1 | |
| SCHEMBL4714598 | 0.89 | BDKRB1 (0.58) | BDKRB1HTR2AHTR2CHTR2BL3MBTL3 | |
| SCHEMBL5629162 | 0.87 | BDKRB1 (0.78) | BDKRB1HTR2AHTR2CHTR2BL3MBTL3 | |
| SCHEMBL4717372 | 0.87 | BDKRB1 (0.56) | BDKRB1HTR2AHTR2CHTR2BGRM1 | |
| SCHEMBL4716342 | 0.86 | BDKRB1 (0.77) | BDKRB1HTR2AHTR2CHTR2BGRM1 | |
| SCHEMBL5630506 | 0.85 | BDKRB1 (0.61) | BDKRB1 | |
| SCHEMBL4714572 | 0.84 | BDKRB1 (0.59) | BDKRB1L3MBTL3 | |
| SCHEMBL4760693 | 0.84 | BDKRB1 (0.66) | BDKRB1HTR2AHTR2CHTR2BGRM1 | |
| SCHEMBL4717438 | 0.83 | BDKRB1 (0.58) | BDKRB1HTR2AHTR2CHTR2BEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | claimed |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | disclosed |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | disclosed |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | BDKRB1, BDKRB2, NPBWR1 | BDKRB1 1/4885HTR2A 742/4885HTR2C 1740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.